Unnatural Products, founded with the mission to revolutionize drug discovery, leverages AI-enhanced technology to develop novel drugs targeting previously undruggable proteins. The company specializes in engineering passively permeable, macrocyclic peptides that can reach complex drug targets beyond the capabilities of traditional small molecules and biologics. Their innovative approach aims to address a significant portion of drug targets that impact human health but have remained out of reach for existing therapeutic modalities.
Notable figures affiliated with Unnatural Products include leading experts in AI and drug discovery, though specific names are not provided. The company has attracted significant attention and investment from key players in the biotech and pharmaceutical industries. Their pioneering work in creating macrocyclic peptides has positioned them as a transformative force in the field, potentially unlocking treatments for a wide array of conditions previously deemed untreatable.
